Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma
In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a patient with multiple myeloma and progressive disease.
CASE SUMMARY
- A 72-year-old man was diagnosed 6 years ago with multiple myeloma, with 60% plasma cells and translocation 14;20.
- Medical history: respiratory infections (2 episodes of pneumonia and multiple episodes of bronchitis over prior 10 years)
- He received 5 prior lines of therapy, most recently chimeric antigen receptor T-cell infusion
- He now presents with progressive disease (elevated free light chain, creatinine level of 2.3 mg/dL)
- ECOG performance status: 2
CASE UPDATE
Talquetamab is initiated via step-up dosing (SUD) up to 800 μg/kg every 2 weeks (Q2W).
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More
